Prognostic Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic Stenosis Patients after TAVI
- PMID: 34201104
- PMCID: PMC8228319
- DOI: 10.3390/medicina57060588
Prognostic Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic Stenosis Patients after TAVI
Abstract
Background and objectives: In this study, we aimed to evaluate whether the systemic immune-inflammation index (SII) has a prognostic value for major adverse cardiac events (MACEs), including stroke, re-hospitalization, and short-term all-cause mortality at 6 months, in aortic stenosis (AS) patients who underwent transcatheter aortic valve implantation (TAVI). Materials and Methods: A total of 120 patients who underwent TAVI due to severe AS were retrospectively included in our study. The main outcome of the study was MACEs and short-term all-cause mortality at 6 months. Results: The SII was found to be higher in TAVI patients who developed MACEs than in those who did not develop them. Multivariate Cox regression analysis revealed that the SII (HR: 1.002, 95%CI: 1.001-1.003, p < 0.01) was an independent predictor of MACEs in AS patients after TAVI. The optimal value of the SII for MACEs in AS patients following TAVI was >1.056 with 94% sensitivity and 96% specificity (AUC (the area under the curve): 0.960, p < 0.01). We noted that the AUC value of SII in predicting MACEs was significantly higher than the AUC value of the C-reactive protein (AUC: 0.960 vs. AUC: 0.714, respectively). Conclusions: This is the first study to show that high pre-procedural SII may have a predictive value for MACEs and short-term mortality in AS patients undergoing TAVI.
Keywords: SII; TAVI; inflammation; major adverse cardiac events; mortality.
Conflict of interest statement
All authors declare that they do not have a conflict of interest.
Figures
References
-
- Masson J.B., Kovac J., Schuler G., Ye J., Cheung A., Kapadia S., Tuzcu M.E., Kodali S., Leon M.B., Webb J.G. Transcatheter aortic valve implantation: Review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc. Interv. 2009;2:811–820. doi: 10.1016/j.jcin.2009.07.005. - DOI - PubMed
-
- Toutouzas K., Stathogiannis K., Latsios G., Synetos A., Drakopoulou M., Penesopoulou V., Michelongona A., Tsiamis E., Tousoulis D. Biomarkers in aortic valve stenosis and their clinical significance in transcatheter aortic valve implantation. Curr. Med. Chem. 2019;26:864–872. doi: 10.2174/0929867324666170727110241. - DOI - PubMed
-
- Takagi H., Kuno T., Hari Y., Nakashima K., Yokoyama Y., Ueyama H., Ando T., ALICE (All-Literature Investigation of Cardiovascular Evidence) Group Prognostic impact of baseline C-reactive protein levels on mortality after transcatheter aortic valve implantation. J. Card. Surg. 2020;35:974–980. doi: 10.1111/jocs.14499. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
